Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Novel bispecific CAR shows promise

Hossain N et al. ASH 2018, Abstract 490.

Publish date:: February 4, 2019

Key clinical point: A novel bispecific CAR shows promising safety and efficacy in B-cell malignancies.

Major finding: Grade 1 cytokine release syndrome occurred in five patients, and grade 2 CRS occurred in one patient; there were no dose-limiting toxicities.

Study details: A phase 1 dose escalation study of nine patients.

Disclosures: Dr. Hossain reported having no financial disclosures.

Source: Hossain N et al. ASH 2018, Abstract 490.

Citation:

SOURCE: Hossain N et al. ASH 2018, Abstract 490.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in B Cell Lymphoma

Four-item prognostic index predicts survival in adult Burkitt lymphoma,

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

ZUMA-12 study shows frontline axi-cel has substantial activity in high-risk large B-cell lymphoma,

Pediatric regimens better for adolescents/young adults with aggressive B-cell NHL,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,